What is the 13F Pro Quality Score for PACS?

13F Pro ranks PACS Group, Inc. (PACS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PACS's current score at https://13fpro.ai/company/PACS (free sign-up required for the full ranking).

Which hedge funds own the most PACS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PACS include COHEN & STEERS,, FMR, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/PACS as soon as new 13F filings post.

Where does 13F Pro source PACS data?

All PACS Group, Inc. fundamentals and ownership data come directly from SEC EDGAR. PACS Group, Inc. files with the SEC under CIK 2001184. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PACS in?

PACS Group, Inc. (PACS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PACS's revenue?

Per PACS Group, Inc.'s latest 10-Q filed with the SEC on 2026-08-04, the biggest revenue drivers are: Patient and resident service revenue ($2,847.5M, +10.1% YoY); Skilled nursing services revenue ($2,754.7M, +8.8% YoY); Other revenue ($1.0M, +99.2% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/PACS.

What are PACS's largest expenses?

PACS Group, Inc.'s latest 10-Q reports these as the largest expense items: Cost of services ($2,164.1M, +5.8% YoY); General and administrative expense ($226.6M, +13.9% YoY); Rent - cost of services ($190.2M, +1.1% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (six months ended June 30, 2026).

How often is PACS research updated on 13F Pro?

PACS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PACS Group, Inc.(PACS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 2001184 PACS stock profile & AI dashboard →

13F Pro Quality Score

71.2/100

Rank #197 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

86.4/100

Profitability

54.4/100

Balance Sheet

69.2/100

Earnings Quality

85.1/100

Free Cash Flow

56.3/100

Institutional Flow

44.5/100

Revenue Scale

79.4/100

Dilution Risk

56.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PACS Scores 71/100

exact factor attribution · 2026-09-11

PACS's composite is driven by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.3 pts

86th pct

Scale

+4.4 pts

79th pct

Earnings quality

+3.5 pts

85th pct

Earnings growth

+2.4 pts

98th pct

Capital efficiency

+1.9 pts

69th pct

Free cash flow

+0.9 pts

56th pct

Profitability

+0.7 pts

54th pct

Shareholder dilution

+0.3 pts

57th pct

Institutional flow

-0.3 pts

45th pct

Latest change (2026-08-04): 70 → 66 · ↓ Revenue growth 92→71; ↓ Free cash flow 68→49; despite ↑ Profit margin 51→60

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

PACS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for PACS Group, Inc. (PACS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PACS at 71.2/100 on a 32-signal composite quality model, placing it at rank #197 of 2,961 stocks — the top 10% of the AI-ranked universe. PACS scores in the top quartile across revenue growth (86.4), earnings quality (85.1), revenue scale (79.4). Based on the latest XBRL financial filings (Q2 2026), PACS Group, Inc. reports quarterly revenue of $1.4B, net income of $76.4M, an operating margin of 7.7%. Top institutional holders of PACS by reported 13-F value include COHEN & STEERS, FMR, BlackRock, based on the most recent SEC filings. PACS trades on the NYSE exchange and files with the SEC under CIK 2001184. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PACS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PACS Group, Inc. directly from SEC EDGAR. PACS Group, Inc.'s 13F Pro composite quality score has ranged between 56 and 71 since 2025, currently 71.2 — a stable long-term trajectory across 49 quarterly and live scoring snapshots.

✦

Fun facts about PACS Group, Inc.

Quirks, history, and lore behind PACS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare services company · post-acute care focused · listed on NYSE · headquartered in Utah.
2
The Numbers
Revenue has grown to roughly $3–4 billion annually, and the company operates hundreds of facilities across more than a dozen states — a rapid expansion for a relatively young public company.
3
The History
Founded in the 2000s and built through aggressive acquisition of skilled nursing and assisted living facilities, it went public on the NYSE in 2024 in one of the sector's notable recent IPOs.
4
The Secret
Its business model centers on acquiring and turning around underperforming skilled nursing facilities — essentially a value-add operator in a corner of healthcare most investors ignore.
5
The Lore
It targets the unglamorous world of skilled nursing facilities and transitional care — the places patients land after a hospital stay — and has quietly become one of the largest operators in that niche.
6
The Giveaway
Its ticker is four letters, its home is Farmington, Utah, and its name is literally an acronym standing for Post-Acute Care Solutions — welcome to the SNF hustle.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving PACS's Business? Latest 10-Q Breakdown

✓ 30/30 datapoints verified

AI-extracted from PACS Group, Inc.'s 10-Q filed 2026-08-04 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

PACS Group reported $2.85B in total revenue for H1 2026, up 10.1% YoY, with net income of $157M (+97.9% YoY) driven by 9.1% patient revenue growth and operational efficiency improvements.

Biggest Revenue Drivers

Patient and resident service revenue$2,847.5M+10.1% YoY

Driven by increased skilled nursing services revenue (+8.8%), higher occupancy rates (90.8% same-store vs 89.3% prior year), and Medicaid rate increases (+3.6%).

Biggest Revenue Drivers

Total revenue: $2.85B+10.1% YoY

Patient and resident service revenue$2,847.5M+10.1% YoY

Driven by increased skilled nursing services revenue (+8.8%), higher occupancy rates (90.8% same-store vs 89.3% prior year), and Medicaid rate increases (+3.6%).

Within Patient and resident service revenue

Skilled nursing services revenue$2,754.7M+8.8% YoY

Increase of 192,244 patient days (+3.7%) from expanded bed count and occupancy gains; same-store revenue grew 6.9%.

Other revenue$1.0M+99.2% YoY

Primarily lease income from arrangements where company acts as lessor.

Largest Expense Items

Cost of services$2,164.1M+5.8% YoY

Salaries and wages increased $65M (+5.1%); administrative facility expenses rose $33.6M, primarily liability insurance (+$28.8M).

General and administrative expense$226.6M+13.9% YoY

Salary increases of $20.1M and stock-based compensation of $46.2M, partially offset by $26.9M decrease in legal fees vs prior year.

Rent - cost of services$190.2M+1.1% YoY

Increase from new facilities with operating leases and annual escalators, offset by real estate acquisitions reducing lease obligations.

Depreciation and amortization$38.2M+47.6% YoY

Increase attributable to acquisitions and new real estate obtained since June 30, 2025.

Margins: Operating income surged 78.3% YoY to $229.4M, with operating margin improving to 8.1% from 5.0% prior year, driven by revenue growth outpacing cost increases. Adjusted EBITDA margin benefited from operational efficiencies and Medicaid rate improvements.

Watch Items from the Filing

Multiple DOJ Civil Investigative Demands ongoing: False Claims Act investigations on PDPM billing practices, COVID-era 1135 waiver claims, and anti-kickback allegations; SEC investigation into accounting, financial reporting, and internal controls.
Material weaknesses in internal control over financial reporting identified; controls over revenue recognition and variable consideration estimates not yet fully remediated despite remediation efforts.
Securities class action (Manchin) and derivative litigation alleging multi-year scheme to inflate revenue via COVID waiver exploitation, unnecessary therapy billing, and falsified documentation; motion to dismiss fully briefed as of June 4, 2026.
California geographic concentration: 140 of 324 facilities (43%) and 16,132 of 35,631 beds (45%) located in California; vulnerability to local economic, regulatory, and natural disaster risks.
Founders Jason Murray and Mark Hancock hold substantial control of outstanding common stock; company operates as 'controlled company' under NYSE rules, limiting certain governance protections.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$1.4B

Net Income

Q2 2026

$76.4M

Operating Margin

Q2 2026

7.7%

ROIC

Q2 2026

32.2%

D/E Ratio

Q2 2026

0.22

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+29.3% YoY

$5.29BFY 2025

FY22 $2.42BFY23 $3.11BFY24 $4.09BFY25 $5.29B

Net Income

+243.5% YoY

$191.5MFY 2025

FY22 $150.5MFY23 $112.9MFY24 $55.8MFY25 $191.5M

Operating Income

+151.6% YoY

$309.6MFY 2025

FY22 $229.4MFY23 $207.8MFY24 $123.1MFY25 $309.6M

EPS (Diluted)

+221.1% YoY

$1.22FY 2025

FY22 $0.04FY23 $0.88FY24 $0.38FY25 $1.22

Total Assets

+6.5% YoY

$5.58BFY 2025

FY22 —FY23 $3.51BFY24 $5.24BFY25 $5.58B

Total Debt

-16.2% YoY

$357.7MFY 2025

FY22 —FY23 $212.5MFY24 $426.8MFY25 $357.7M

Op. Cash Flow

+10.0% YoY

$404.2MFY 2025

FY22 $92.6MFY23 $63.7MFY24 $367.3MFY25 $404.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$5.29B +29.3%	$4.09B +31.4%	$3.11B +28.5%	$2.42B	—
Net Income	$191.5M +243.5%	$55.8M -50.6%	$112.9M -25.0%	$150.5M	—
Operating Income	$309.6M +151.6%	$123.1M -40.8%	$207.8M -9.4%	$229.4M	—
EPS (Diluted)	$1.22 +221.1%	$0.38 -56.8%	$0.88 +2407.1%	$0.04	—
Total Assets	$5.58B +6.5%	$5.24B +49.3%	$3.51B	—	—
Total Debt	$357.7M -16.2%	$426.8M +100.8%	$212.5M	—	—
Operating Cash Flow	$404.2M +10.0%	$367.3M +476.7%	$63.7M -31.2%	$92.6M	—

Get alerted when PACS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PACS Group, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PACS

COHEN & STEERS, INC.
$355.8M8,343,381 sh
FMR LLC
$264.7M6,207,375 sh
BlackRock, Inc.
$177.2M4,155,408 sh
Crewe Advisors LLC
$141.0M3,307,188 sh
AMERICAN CENTURY COMPANIES INC
$132.5M3,108,196 sh
AMERIPRISE FINANCIAL INC
$85.1M1,995,116 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$84.5M1,982,621 sh
VANGUARD CAPITAL MANAGEMENT LLC
$78.6M1,843,496 sh
Alyeska Investment Group, L.P.
$65.6M1,539,065 sh
DIMENSIONAL FUND ADVISORS LP
$52.5M1,230,728 sh

Fund	Value	Shares
COHEN & STEERS, INC.	$355.8M	8,343,381
FMR LLC	$264.7M	6,207,375
BlackRock, Inc.	$177.2M	4,155,408
Crewe Advisors LLC	$141.0M	3,307,188
AMERICAN CENTURY COMPANIES INC	$132.5M	3,108,196
AMERIPRISE FINANCIAL INC	$85.1M	1,995,116
VANGUARD PORTFOLIO MANAGEMENT LLC	$84.5M	1,982,621
VANGUARD CAPITAL MANAGEMENT LLC	$78.6M	1,843,496
Alyeska Investment Group, L.P.	$65.6M	1,539,065
DIMENSIONAL FUND ADVISORS LP	$52.5M	1,230,728

Companies Similar to PACS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ENSG

ENSIGN GROUP, INC

AI score

Similar quality profile · 5 shared holders

Clark Capital Management Group, Inc.T. Rowe Price Investment Management, Inc.Eversept Partners, LP

INFU

InfuSystem Holdings, Inc

AI score

Similar quality profile · 4 shared holders

Sentinus, LLC Catalyst Funds Management Pty Ltd AXQ CAPITAL, LP

NHC

NATIONAL HEALTHCARE CORP

AI score

Similar quality profile · 7 shared holders

T. Rowe Price Investment Management, Inc.Eversept Partners, LP ROYCE & ASSOCIATES LP

HCSG

HEALTHCARE SERVICES GROUP INC

AI score

Similar quality profile · 12 shared holders

ROYCE & ASSOCIATES LP 8 KNOTS MANAGEMENT, LLC HUSSMAN STRATEGIC ADVISORS, INC.

EHAB

Enhabit, Inc.

AI score

Similar quality profile · 2 shared holders

8 KNOTS MANAGEMENT, LLC Kent Lake PR LLC

UFPT

UFP TECHNOLOGIES INC

AI score

Similar quality profile · 4 shared holders

ROYCE & ASSOCIATES LP Peterson Wealth Services Yorktown Management & Research Co Inc

IRWD

IRONWOOD PHARMACEUTICALS INC

AI score

Similar quality profile · 3 shared holders

AXQ CAPITAL, LP ROYCE & ASSOCIATES LP C M BIDWELL & ASSOCIATES LTD

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 10 shared holders

Alyeska Investment Group, L.P.ZACKS INVESTMENT MANAGEMENT Jackson Creek Investment Advisors LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PACS on your watchlist

Track score changes the day PACS Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PACS a good stock to buy?

13F Pro's AI-powered analysis of PACS Group, Inc. (PACS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PACS are available on the PACS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PACS is classified as a mid company.

Which hedge funds own PACS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PACS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PACS Group, Inc.'s investment landscape.